Firefly Neuroscience Announces Termination Of CFO Paul Krzywicki Effective September 24

Firefly Neuroscience Strengthens Non-Invasive Brain-Computer Interface Growth Strategy

Firefly Neuroscience announced a strategic focus on its Brain-Computer Interface (BCI) growth, supported by its AI foundation model and the commercial availability of its Versus platform.

Gold Fields, Harmony Gold Mining, Anglogold Ashanti And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

U.S. stock futures fell as gold and silver prices slid, sending Gold Fields down 16% and other precious-metal stocks lower in premarket trading.

Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss narrowed; Game Your Game led gainers, Masonglory fell.

Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care

Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.

Firefly Neuroscience shares are trading higher after the company announced a partnership with NeuroSigma to expand access to the Monarch eTNS System through its Evoke clinician network.

Firefly Neuroscience Partners With NeuroSigma To Expand Clinician Awareness Of And Access To The Monarch eTNS System

Collaboration to use Firefly’s growing nationwide network of Evoke™ clinician customers. The Monarch eTNS® System is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder ("ADHD")